We next assessed the therapeutic response to CD25 depletion and observed that RT + aCD25-treated PDG-Ink4a glioblastoma-bearing mice did not experience any survival benefit over RT monotherapy (Extended Data Fig. 8h and Supplementary Table 10). The gene discussed is PHGDH; the disease is glioblastoma.